vor 4 Jahren

Life Sciences Report 2019 / 2020

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

14 Life

14 Life Sciences Report – Drug Discovery and Development: Pharma attractiveness of the location and a commitment of the companies to the capital region. They range from close cooperation with regional biotech startups, cooperation with the scientific community to expansion of locations to settlement. investing € 100 million into new facilities at Oranienburg to expand its production capacity. The inauguration of the new production unit was accompanied by Chancellor Angela Merkel in June 2017, and through this expansion 180 new jobs have been created. In last years, BERLIN-CHEMIE has invested more than € 80 million in the expansion of its headquarter in Berlin-Adlershof and has established itself as an important player in the region by organising the renowned Congress for healthcare networkers. Large parts of Sanofi‘s marketing and sales teams work from Berlin. Sanofi and the Charité/Berlin Institute of Health (BIH) have several joint research projects underway, investigation treatments for various conditions. Among other things, Sanofi has been funding five BIH projects since 2018 through its iAward Europe program. These are intended to move innovative academic research more quickly to the clinical phase. In addition, Sanofi maintains numerous collaborations with partners in the HealthCapital, including long-term strategic partnerships with the Medicine and Health Congress and the World Health Summit. At Sanofi, digitalisation is taking place across the entire value chain. A new cooperation with Google also shows the relevance of cross-sector cooperation. Together with Google, Sanofi will be setting up a virtual innovation laboratory, using data technologies to better understand diseases and gain insights into patients. At its free health exhibition at the Sanofi Showroom on Potsdamer Platz, visitors of all ages are invited to explore the human body interactively and have fun while learning about the topic of health. After the acquisition of Shire in January 2019, Takeda has become the leader in rare diseases. With more than 1,200 employees at Takeda’s headquarters in Berlin (including the former Shire local headquarter) and its manufacturing plant in Oranienburg the company has a strong footprint in the Berlin-Brandenburg region and is a proud partner for its stakeholders in the healthcare system. Takeda has been B. Braun Melsungen has three locations and a total of over 1,000 employees in Berlin: with a competence centre for the production of sterile injection solutions in vials and glass and plastic ampoules, a competence centre for products for the treatment of vascular diseases that develops, manufactures, and markets cardiac catheters, stents and vascular implants, as well as the Aesculap Academy. Around €100 million in current and planned investments in its Berlin production facilities illustrate B. Braun’s commitment to the capital. Pfizer has its German headquarters in Berlin since 2008. Peter Albiez, Chairman of the Management Board, is the committed spokesman for HealthCapital and closely associated with the cluster community. Since 2014, Pfizer has been active in the region with the Pfizer Healthcare Hub Berlin in order to develop digital solutions through cooperation. The hub is the point of contact for startups - for example with the “Startup Sprechstunde”, which takes place several times a year. DR. KADE is also showing its ties to Berlin with extensive investments. On the one hand, the company moved into its new administrative headquarters in the Ullsteinhaus and used the space freed up at the company’s headquarters also in Tempelhof-Schöneberg to expand its production facilities. The Berlin based company with more than 130 years of history has added additional products to its portfolio through recent acquisitions and has also demonstrated an eye for innovation by investing in Berlin’s startups. These current examples are only a selection of activities of the pharmaceutical industry in Berlin-Brandenburg. They illustrate how much trust big pharma has in the capital region of Germany. “Sanofi has deliberately located its headquarters for Germany in Berlin. What makes the Berlin-Brandenburg region particularly strong for Sanofi and the healthcare sector is the unique concentration and networking of politics, associations, science, clinics, industrial healthcare, and startups. Political decision-makers and many top researchers are located here. If you want to participate, you need to be here on the ground.” © Sanofi Dr Fabrizio Guidi CEO of Sanofi in Germany

Life Sciences Report – Drug Discovery and Development: Pharma 15 You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it. Innovation for better health. Our commitment is to bring to patients around the world quality medicines for use in diagnosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with expertise of innovative partners from science and industry. The success of this work is evidenced in new medicines for areas with significant unmet medical need such as oncology, cardiovascular and blood diseases, as well as gynecology and ophthalmology. Our aim is a better quality of life for all.

Publications in English

Publikationen auf deutsch